Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

被引：1
|
作者：
Venugopal, Sangeetha [1 ]
Kadia, Tapan M. [1 ]
Ravandi, Farhad [1 ]
DiNardo, Courtney D. [1 ]
Daver, Naval [1 ]
Borthakur, Gautam [1 ]
Konopleva, Marina [1 ]
Garcia-Manero, Guillermo [1 ]
Montalban-Bravo, Guillermo [1 ]
Maiti, Abhishek [1 ]
Yilmaz, Musa [1 ]
Issa, Ghayas C. [1 ]
Chien, Kelly S. [1 ]
Pierce, Sherry A. [1 ]
Kantarjian, Hagop [1 ]
Short, Nicholas J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153960
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
794
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
    Danielle Hammond
    Sanam Loghavi
    Sa A. Wang
    Marina Y. Konopleva
    Tapan M. Kadia
    Naval G. Daver
    Maro Ohanian
    Ghayas C. Issa
    Yesid Alvarado
    Nicholas J. Short
    Koji Sasaki
    Naveen Pemmaraju
    Guillermo Montalban-Bravo
    Curtis A. Lachowiez
    Abhishek Maiti
    Guillermo Garcia-Manero
    Elias J. Jabbour
    Gautam Borthakur
    Farhad Ravandi
    Koichi Takahashi
    Sherry R. Pierce
    Hagop M. Kantarjian
    Courtney D. DiNardo
    Blood Cancer Journal, 13
  • [32] Impact of cytogenetics on the outcome of patients undergoing allogeneic HSCT from HILA-identical siblings for MIDS or secondary AML:: a retrospective analysis of the EBMT-CLWP
    Onida, F
    Brand, R
    van Biezen, A
    Runde, V
    Barge, R
    Verdonck, L
    Finke, J
    Beelen, D
    Martino, R
    Fernández-Ranada, J
    Niederwieser, D
    de Witte, T
    BONE MARROW TRANSPLANTATION, 2005, 35 : S36 - S37
  • [33] Impact of cytogenetics on outcome of patients with MDS or secondary AML undergoing allogeneic HSCT from HLA-Identical siblings:: A retrospective analysis of the EBMT-CLWP.
    Onida, Francesco
    Brand, Ronald
    van Biezen, Anja
    Barge, Renee M.
    Verdonck, Leo F.
    Finke, Jurgen
    Beelen, Dietrich
    Martino, Rodrigo
    Fernandez-Ranada, Jose M.
    Niederwieser, Dietger
    Kroeger, Nicolaus
    de Witte, Theo
    BLOOD, 2006, 108 (11) : 750A - 750A
  • [34] Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)
    Bell, Jill A.
    Galaznik, Aaron
    Farrelly, Eileen
    Murty, Sharanya
    Ogbonnaya, Augustina
    Eaddy, Michael T.
    Fram, Robert J.
    Faller, Douglas V.
    Kota, Vamsi
    BLOOD, 2017, 130
  • [35] Treatment Patterns and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMA) in the United States (US)
    Pardee, Timothy S.
    Oschwald, Jessica
    Ma, Esprit
    Xu, Tao
    Montez, Melissa
    Ramsingh, Giridharan
    Hong, Wan-Jen
    Choi, Michelle
    Flahavan, Evelyn M.
    BLOOD, 2020, 136
  • [36] Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)
    Walker, Alison R.
    Metzeler, Klaus H.
    Geyer, Susan
    Becker, Heiko
    Schwind, Sebastian
    Whitman, Susan P.
    Curfman, John
    Wu, Yue-Zhong
    Perrotti, Danilo
    Klisovic, Rebecca B.
    Garzon, Ramiro
    Blum, William
    Marcucci, Guido
    BLOOD, 2011, 118 (21) : 430 - 430
  • [37] Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
    Patwardhan, Pallavi
    Landsteiner, Adrienne
    Lal, Lincy S.
    Geevarghese, Lincy
    Le, Lisa
    Nandal, Savita
    Cuker, Adam
    ANNALS OF HEMATOLOGY, 2022, 101 (01) : 11 - 19
  • [38] Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
    Pallavi Patwardhan
    Adrienne Landsteiner
    Lincy S. Lal
    Lincy Geevarghese
    Lisa Le
    Savita Nandal
    Adam Cuker
    Annals of Hematology, 2022, 101 : 11 - 19
  • [39] INSULIN REQUIREMENT IN PATIENTS WITH SECONDARY FAILURE OF SULFONYLURIA TREATMENT - A RETROSPECTIVE ANALYSIS
    RATZMANN, KP
    SCHIMKE, E
    ZEITSCHRIFT FUR KLINISCHE MEDIZIN-ZKM, 1992, 47 (02): : 58 - 65
  • [40] Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study
    Chung, Woonbok
    Taverna, Pietro
    Lyons, John F.
    Hao, Yong
    Azab, Mohammad
    Kantarjian, Hagop M.
    Kropf, Patricia
    Issa, Jean-Pierre
    BLOOD, 2013, 122 (21)
12345